Abbott Recall Of Millions Of Glucose Test Strips Will Cost Under $20 Mil.
This article was originally published in The Gray Sheet
Executive Summary
Abbott is recalling more than 350 million glucose testing strips used in several of its blood glucose monitoring systems because the strips may yield falsely low blood glucose results, FDA and the firm announced Dec. 22.
You may also be interested in...
Regulatory News In Brief
FDA clears test for kidney transplant patients
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.